Page last updated: 2024-09-05

iclaprim and Skin Diseases, Infectious

iclaprim has been researched along with Skin Diseases, Infectious in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Charrier, C; Hawser, S; Huang, DB1
Huang, D; Lodise, T; Patel, N1
Corey, GR; Huang, DB; Noviello, S1
Brandt, R; Hadvary, P; Hawser, S; Islam, K; Krievins, D1

Reviews

1 review(s) available for iclaprim and Skin Diseases, Infectious

ArticleYear
Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
    Expert review of anti-infective therapy, 2018, Volume: 16, Issue:11

    Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Bacterial; Folic Acid Antagonists; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Skin Diseases, Infectious

2018

Trials

1 trial(s) available for iclaprim and Skin Diseases, Infectious

ArticleYear
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Skin Diseases, Infectious; Staphylococcus aureus; Vancomycin; Young Adult

2009

Other Studies

2 other study(ies) available for iclaprim and Skin Diseases, Infectious

ArticleYear
Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
    Diagnostic microbiology and infectious disease, 2020, Volume: 97, Issue:1

    Topics: Africa; Anti-Bacterial Agents; Asia; Europe; Folic Acid Antagonists; Global Health; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Latin America; Microbial Sensitivity Tests; Middle East; Population Surveillance; Pyrimidines; Skin; Skin Diseases, Infectious; Tetrahydrofolate Dehydrogenase; United States

2020
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
    Clinical drug investigation, 2018, Volume: 38, Issue:10

    Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cost Savings; Folic Acid Antagonists; Hospitalization; Humans; Pyrimidines; Skin Diseases, Infectious; Vancomycin

2018